Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R.; Vigo‐Pelfrey, C.; Kholodenko, D.; Barbour, R.; Johnson‐Wood, K.; Galasko, D.; Chang, L.; Miller, B.; Clark, C.; Green, R.; Olson, D.; Southwick, P.; Wolfert, R.; Munroe, B.; Lieberburg, I.; Seubert, P.; Schenk, D.

doi:10.1002/ana.410380413

Cited by 701Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCerebrospinal fluid and hydrocephalus

Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B. +9 more·1995·Annals of Neurology

DOI 10.1002/ana.410380413

Open this paper in CoChat — free account

Abstract

In this clinical study, the cerebrospinal fluid (CSF) level of a Novemberel form of the β‐amyloid peptide (Aβ) extending to position 42 (Aβ 42) was determined in patients with Alzheimer's disease (AD) as well as controls. In addition to measurement of CSF Aβ 42 levels, total Aβ peptides, microtubule‐associated protein τ, and apolipoprotein E (ApoE) genotype were also assessed. It is interesting that CSF Aβ 42 levels were found to be significantly lower in AD patients relative to controls, whereas total Aβ levels were not. Aβ 42 has recently been shown to preferentially deposit in the brain tissue of patients with AD, suggesting that diminished clearance may account for its reduction in CSF. As previously reported, τ levels were increased in AD patients; however, neither Aβ 42 nor τ levels were apparently influenced by the ApoE genotype.

Integrity signals

Registry

Crossref · 10.1002/ana.410380413

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

It is well established that Aβ42 declines in the CSF of patients with typical late onset AD.
“It is well established that A␤42 declines in the CSF of patients with typical late onset AD (Motter et al., 1995;Nitsch et al., 1995;Kanai et al., 1998;Andreasen et al., 1999)”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Motter et al., 1995
CSF Aβ42 levels are typically reduced in dementia of the Alzheimer type (DAT), reflecting its aggregation and deposition as amyloid in the brain.
“Levels of CSF Aβ42 are typically reduced in dementia of the Alzheimer type (DAT),8-11 reflecting its aggregation and deposition as amyloid in the brain,12”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [11]

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Development of a Rating Scale for Primary Depressive Illness
Hamilton, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410 · see citing works
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · see citing works
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786 · see citing works
. Cerebral blood flow in dementia.
Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W. R., & Symon, L. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510088009 · Cited by 3,186 · see citing works
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · see citing works
Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · see citing works
Self-citation
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331 · see citing works
Apolipoprotein E genotyping by one-stage PCR
Wenham, P. R., Price, W. H., & Blundell, G. (1991) · The Lancet · doi:10.1016/0140-6736(91)92823-k · Cited by 1,070 · see citing works
Dementia: A Clinical Approach
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-351_2 · Cited by 858 · see citing works
The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease
Price, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90006-6 · Cited by 818 · see citing works
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799 · see citing works
Hypothesis: Microtubule Instability and Paired Helical Filament Formation in the Alzheimer Disease Brain Are Related to Apolipoprotein E Genotype
Strittmatter, W. J., Weisgraber, K. H., Goedert, M., Saunders, A. M., Huang, D., Corder, E. H., Dong, L., Jakes, R., Alberts, M. J., Gilbert, J. R., et al. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1019 · Cited by 433 · see citing works
SAMPLE PREPARATION FROM BLOOD, CELLS, AND OTHER FLUIDS
Kawasaki, E. S. (1990) · Elsevier eBooks · doi:10.1016/b978-0-12-372180-8.50022-6 · Cited by 423 · see citing works
Clinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias
Galasko, D., Hansen, L. A., Katzman, R., Wiederholt, W. C., Masliah, E., Terry, R. D., Hill, L. R., Lessin, P. J., & Thal, L. J. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210060013 · Cited by 407 · see citing works
Self-citation
Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid
Vigo‐Pelfrey, C., Lee, D., Keim, P., Lieberburg, I., & Schenk, D. B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09841.x · Cited by 385 · see citing works
Self-citation
Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques.
Dickson, D. W., Farlo, J., Davies, P., Crystal, H., Fuld, P. A., & Yen, S. H. (1988) · PubMed Central · Cited by 383 · see citing works
Brain Levels of Microtubule‐Associated Protein τ Are Elevated in Alzheimer's Disease: A Radioimmuno‐Slot‐Blot Assay for Nanograms of the Protein
Khatoon, S., Grundke, I., & Iqbal, K. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09432.x · Cited by 304 · see citing works
Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease
Vigo‐Pelfrey, C., Seubert, P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B. L., Lieberburg, I. M., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.788 · Cited by 225 · see citing works
Self-citation
Abnormal Metabolism of γ-Trace Alkaline Microprotein
GRUBB, A. O., Jensson, Ó., Guðmundsson, G., Árnason, A., Löfberg, H., & Malm, J. (1984) · New England Journal of Medicine · doi:10.1056/nejm198412133112406 · Cited by 150 · see citing works
Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Voorde, A., Martin, J.-J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 145 · see citing works
Dementia
Friedland, R. P. (1992) · Neurology · doi:10.1212/wnl.42.8.1648-c · Cited by 119 · see citing works
Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's disease
Nakamura, T., Shoji, M., Harigaya, Y., 渡辺, 光., Hosoda, K., Cheung, T. T., Shaffer, L. M., Golde, T. E., Younkin, L. H., Younkin, S. G., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410360616 · Cited by 101 · see citing works

Flagged first, then by citations

Research works printed but not linked: 2

McKann G, 1984, Clinical diagnosis of AD, Neurology, 34, 939
Mann DMA, 1992, The time course of pathological events in Down's syndrome with particular reference to the involvement of microglial cells and deposits of β/A4, Neurodegeneration, 1, 201

Sorted by citations

Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · see citing works
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works
Self-citation
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · see citing works
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works
Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · see citing works
“…Ab decline as Ab is deposited in the Tg2576 brain It is well established that Ab42 declines in the CSF of patients with typical late onset AD (Motter et al., 1995; Nitsch et al., 1995; Kanai et al., 1998; Andreasen et al., 1999), and this decrease could conceivably cause plasma Ab42 to…”
Background
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000 · see citing works
Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis
Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M. E., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12817 · Cited by 1,009 · see citing works
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830 · see citing works
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · see citing works
Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works
Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers
Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M., & Selkoe, D. J. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.103754 · Cited by 619 · see citing works
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582 · see citing works
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573 · see citing works
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476 · see citing works
Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology
HUANG, X., MOIR, R. D., TANZI, R. E., BUSH, A. I., & ROGERS, J. T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.012 · Cited by 425 · see citing works
Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382 · see citing works
Cerebrospinal Fluid Tau and β-Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357 · see citing works
Self-citation
Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma
Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331 · see citing works
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327 · see citing works
Sensitive ELISA detection of amyloid‐β protofibrils in biological samples
Englund, H., Sehlin, D., Johansson, A., Nilsson, L. N. G., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04759.x · Cited by 292 · see citing works
Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301 · see citing works
Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment
Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287 · see citing works
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283 · see citing works
High‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients
Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-150359 · Cited by 264 · see citing works
Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease
Itoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256 · see citing works
Amyloid-β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in Plasma
Kuo, Y.-M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., Koo, E. H., Emmerling, M. R., & Roher, A. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2222 · Cited by 230 · see citing works
Self-citation
Soluble Aβ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes
Hong, S., Ostaszewski, B. L., Yang, T., O’Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.027 · Cited by 213 · see citing works
Mouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213 · see citing works
Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42
Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204 · see citing works
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1960 · Cited by 181 · see citing works
Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma
Kontush, A., Berndt, C., Weber, W., Akopyan, V., Arlt, S., Schippling, S., & Beisiegel, U. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00458-5 · Cited by 180 · see citing works
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152 · see citing works
CSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · see citing works
If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
Haass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145 · see citing works
New MRI markers for Alzheimer’s disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements
Clerx, L., Visser, P. J., Verhey, F., & Aalten, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110797 · Cited by 132 · see citing works
β-Amyloid (Aβ) Deposition in the Brains of Aged Orangutans
Gearing, M., Tigges, J., Mori, H., & Mirra, S. S. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00012-2 · Cited by 130 · see citing works
APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42
Prince, J. A., Zetterberg, H., Andreasen, N., Marcusson, J., & Blennow, K. (2004) · Neurology · doi:10.1212/01.wnl.0000128088.08695.05 · Cited by 128 · see citing works
Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease
Ewers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119 · see citing works
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls
Chou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117 · see citing works
Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation
Hong, S., Quintero-Monzon, O., Ostaszewski, B. L., Podlisny, D. R., Cavanaugh, W. T., Yang, T., Holtzman, D. M., Cirrito, J. R., & Selkoe, D. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3272-11.2011 · Cited by 111 · see citing works
Amyloid‐β oligomers are inefficiently measured by enzyme‐linked immunosorbent assay
Stenh, C., Englund, H., Lord, A., Johansson, A., Almeida, C. G., Gellerfors, P., Greengard, P., Gouras, G. K., Lannfelt, L., & Nilsson, L. N. G. (2005) · Annals of Neurology · doi:10.1002/ana.20524 · Cited by 99 · see citing works
Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation
Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. M. (2007) · Annals of Neurology · doi:10.1002/ana.21099 · Cited by 84 · see citing works
The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease
Blennow, K., & Zetterberg, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.012 · Cited by 69 · see citing works
APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?
Jordà‐Siquier, T., Petrel, M., Kouskoff, V., Smailovic, U., Cordelières, F., Frykman, S., Müller, U., Mulle, C., & Barthet, G. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12546 · Cited by 63 · see citing works
Ocular manifestations of Alzheimer's disease in animal models
Parnell, M., Guo, L., Abdi, M., & Cordeiro, M. F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/786494 · Cited by 56 · see citing works
The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently
Shoji, M., Kanai, M., Matsubara, E., Tomidokoro, Y., Shizuka, M., Ikeda, Y., Ikeda, M., Harigaya, Y., Okamoto, K., & Hirai, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00229-3 · Cited by 50 · see citing works
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48 · see citing works
Amyloid β Protein in Plasma as a Diagnostic Marker for Alzheimer’s Disease
Iwatsubo, T. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00015-3 · Cited by 37 · see citing works
VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35 · see citing works
Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1–42 in CSF for the Diagnosis of Alzheimer’s Disease
Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M., & Zhang, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00829 · Cited by 37 · see citing works
Self-citation
Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34 · see citing works
Progress and challenges in the diagnosis of dementia: a critical review
Paraskevaidi, M., Martin-Hirsch, P. L., & Martin, F. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00007 · Cited by 31 · see citing works
PHF and PHF-like fibrils –cause or consequence?
Ihara, Y. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00200-1 · Cited by 28 · see citing works
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25 · see citing works

Cerebrospinal fluid endothelin-1 in Alzheimer's disease and senile dementia of Alzheimer type
Yoshizawa, T., Iwamoto, H., Mizusawa, H., et al. (1992) · Neuropeptides · doi:10.1016/0143-4179(92)90059-6 · Cited by 20 · see citing works
Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease
Shetty, H. U., Holloway, H. W., & Schapiro, M. B. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.2.298 · Cited by 33 · see citing works
Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients
Rösler, N., Wichart, I., & Jellinger, K. A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01514-2 · Cited by 20 · see citing works
Cerebrospinal fluid apolipoprotein E is reduced in Alzheimerʼs disease
Blennow, K., Hesse, C., & Fredman, P. (1994) · Neuroreport · doi:10.1097/00001756-199412000-00032 · Cited by 96 · see citing works
The −491A/T polymorphism of the Apolipoprotein E gene is associated with the ApoEϵ4 allele and Alzheimer's Disease
Ahmed, A. R. H., MacGowan, S. H., Culpan, D., Jones, R. W., & Wilcock, G. K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00126-3 · Cited by 24 · see citing works

Authors: Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., Olson, D., Southwick, P., Wolfert, R., Munroe, B., Lieberburg, I., Seubert, P., & Schenk, D.
Affiliations: University of California San Diego (US)
University of California, Los Angeles (US)
Graduate Hospital (US)
Emory University (US)
Corresponding author: Schenk, D.
ORCID: Galasko, D.
Chang, L.
Miller, B.
Green, R.
Southwick, P.
Venue: Annals of Neurology
Publisher: Wiley
Published: 1995-10
Volume: 38
Issue: 4
Pages: 643-648
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410380413
OpenAlex: W1982341565
Cited by: 701
References: 25
Citations by year: 2026: 12 · 2025: 14 · 2024: 14 · 2023: 6 · 2022: 16 · 2021: 26 · 2020: 16 · 2019: 15 · 2018: 20 · 2017: 20 · 2016: 15 · 2015: 23 · 2014: 15 · 2013: 26 · 2012: 30
FWCI: 17.10
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 3295 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords: Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid clearance, tau protein, APOE genotype
MeSH terms: Aged, Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Enzyme-Linked Immunosorbent Assay, Female, Genotype, Humans, Male, Middle Aged, Molecular Sequence Data, Peptide Fragments, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks